KINNATE BIOPHARMA INC's ticker is KNTE and the CUSIP is 49705R105. A total of 74 filers reported holding KINNATE BIOPHARMA INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 1.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,267 | -72.7% | 8,048 | -40.9% | 0.00% | – |
| Q2 2023 | $41,290 | -73.1% | 13,627 | -44.5% | 0.00% | – |
| Q1 2023 | $153,412 | -15.8% | 24,546 | -17.8% | 0.00% | – |
| Q4 2022 | $182,098 | -65.9% | 29,852 | -33.1% | 0.00% | – |
| Q3 2022 | $534,000 | -26.9% | 44,643 | -23.0% | 0.00% | – |
| Q2 2022 | $731,000 | +278.8% | 57,949 | +237.4% | 0.00% | – |
| Q1 2022 | $193,000 | -59.2% | 17,176 | -35.7% | 0.00% | – |
| Q4 2021 | $473,000 | +6.1% | 26,726 | +38.0% | 0.00% | – |
| Q3 2021 | $446,000 | +262.6% | 19,372 | +268.1% | 0.00% | – |
| Q2 2021 | $123,000 | -85.5% | 5,263 | -80.6% | 0.00% | – |
| Q1 2021 | $847,000 | – | 27,182 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 9,671,643 | $384,738,000 | 41.79% |
| Foresite Capital Management V, LLC | 875,001 | $34,808,000 | 25.78% |
| Vida Ventures Advisors, LLC | 2,747,074 | $109,279,000 | 22.43% |
| VR Adviser, LLC | 1,473,014 | $58,596,000 | 8.62% |
| RA Capital Management | 3,593,052 | $142,932,000 | 2.00% |
| Logos Global Management LP | 569,602 | $22,659,000 | 1.94% |
| Boxer Capital, LLC | 1,064,665 | $42,352,000 | 1.36% |
| Orbimed Advisors | 3,847,929 | $153,071,000 | 1.34% |
| HARVARD MANAGEMENT CO INC | 498,001 | $19,810,000 | 1.07% |
| DAFNA Capital Management LLC | 68,121 | $2,710,000 | 0.81% |